AI Article Synopsis
- Researchers conducted a comprehensive analysis of anti-PIT-1 hypophysitis cases, revealing a new instance linked to immune checkpoint inhibitor therapy.
- All 9 patients had significantly low levels of key hormones like growth hormone and prolactin, with some exhibiting atrophy of the pituitary gland and associations with thymoma and lymphoma.
- The study detected high levels of anti-PIT-1 antibodies and abnormal PIT-1 expression within tumor tissues, shedding light on the autoimmune aspects of paraneoplastic hypophysitis.
Article Abstract
The pathogenesis of anti-pituitary-specific transcription factor-1 (PIT-1) hypophysitis was gradually revealed as cases emerged. Our comprehensive analysis, including all reported cases, identified a new instance of anti-PIT-1 hypophysitis postimmune checkpoint inhibitor therapy. All 9 patients exhibited extremely low growth hormone (GH), prolactin (PRL), and thyroid-stimulating hormone (TSH) levels; 2 had a slightly atrophic pituitary gland; 4 had thymoma, and 5 had malignant neoplasms of diffuse large B-cell lymphoma (DLBCL) and other origins. Patients with thymoma showed multiple autoimmune diseases. HLA-A*24:02 and/or A*02:06 were present in six and DR53 in 5 cases analyzed. High anti-PIT-1 antibody titers and ectopic PIT-1 expression in the cytosol and nucleus of the tumor tissues were observed in patients with thymoma or DLBCL, whereas it was exclusively observed in the nuclei of a bladder cancer patient. These findings provide new insights into the pathophysiology of paraneoplastic autoimmune hypophysitis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/ejendo/lvad179 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!